

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: AI/ML Innovations Inc. (the "Issuer").

Trading Symbol: AIML

Number of Outstanding Listed Securities: 29,081,672

Date: 05/07/2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its final development work on the second generation of its Health Gauge hardware solution, and upgrades to its phone apps and cloud-based platform to improve the efficiency and add additional feature sets. It also furthered its discussions with potential channel partners and other potential users of the technology.

Additionally, the Issuer named Mr Dave Cross as its new CFO in place of Vic Hugo.

The Issuer announced that its subsidiary, Health Gauge, has partnered with the University of Alberta's ST Innovations regarding Neural Network data set validation work in support of Health Gauge's FDA 510k and Health Canada submission processes for clearance as a Class 2 medical device.

Subsequently the Issuer announced that Health Gauge, had entered into a strategic partnership with Lenica Research Group, a leader in the development of innovative, evidence-based tools to improve brain function and enhance athletic performance for the pending commercial launch of Lenica's Peak Cognition sports training platform.

Finally, the Issuer announced that it has entered into a binding Letter of Intent, subject to certain terms and conditions, regarding a strategic partnership and equity interest in the Paris, France based company, Tech2Health, a company with a suite of products for the digital administration of mental health solutions.

2. Provide a general overview and discussion of the activities of management.

During the month, management has been primarily engaged in the improvement of Health Gauge's technology along with development of strategic partners arrangements for HG. Additionally, management was engaged in the conducting of due diligence and negotiations regarding the acquisition of Tech2Health.

3. Describe and provide details of any new products or services developed or offered.

The Issuer entered into a binding Letter of Intent with Tech2Health during the month. As a result of the arrangement with Tech2Health, the Issuer will acquire an interest in a basket of Tech2Health's wellness and health-tech products and services designed to improve an individual's mental well-being by utilizing a unique blend of proprietary digital assets, remote live counselling, and a physical wellness center. Tech2Health has developed a clinically supported and evidence-based methodology consisting of psychotherapies and non-medicinal interventions that apply body and mind healing techniques supported by meditation, relaxation, mindfulness, yoga, sophrology and art therapy, delivered through a secure digital platform.

In addition to its' pre-commercial, digital therapy and remote patient monitoring platform named Alakin, Tech2Health has three established branded mental wellness products - Qookka Live, Qookka Center and Qookka DTx:

Qookka Live (B2B2C subscription model), provides easy access to personalized programs that combine teleconsultations with psychologists and live sessions with certified coaches, with a particular focus on employee mental health services for Tech2Health's corporate clientele.

Qookka Center (B2C and B2B2C models), is a 230m<sup>2</sup> space dedicated to mental health with a team of 8 therapists led by a psychiatrist. Strategically located in Europe's largest technology park in Sophia-Antipolis, France, home to 2,000 companies and more than 30,000 engineers.

Qookka DTx (B2C and B2B2C models), is a digital mental health therapy platform for high chronic anxiety and depressive patients, administered by a psychiatrist.

Alakin (B2B subscription model) In addition to the Qookka service line, Tech2Health has developed Alakin, a full stack SaaS digital therapy and remote patient monitoring platform that allows hospitals and clinics to easily commence a “no code” value-based care program with their patients. Several pilot studies are being readied.

4. Describe and provide details of any products or services that were discontinued.  
None.
5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer entered into an arms length binding LOI with Tech2Health to acquire certain territorial rights and an equity position in Tech2Health:

The two primary commercial components of the Transaction are:

AIML and Tech2Health will participate jointly, on a 70:30 basis, in a privately held AIML subsidiary. This subsidiary will own 100% of the North American rights (USA, Canada, and Mexico) to the exclusive commercial use of all Products, Brands, and Trademarks owned by Tech2Health, in perpetuity (the “Strategic Alliance”). AIML will issue 1.5 million restricted common shares (subject to a minimum 12-month voluntary restriction) from its treasury (at a deemed price of CAD\$0.80 per share) to Tech2Health regarding this Strategic Alliance.

Additionally, AIML will acquire a stake in Tech2Health’s global operations by way of an investment into Tech2Health, in return for 22.22% of Tech2Health’s common share equity (the “Acquisition”). AIML will make payments totaling €2million over an 18-month period in regard to the Acquisition. The funds advanced to Tech2Health by AIML will be used to further Tech2Health’s technologies and market penetration strategies as per a pre-agreed upon use of proceeds plan. AIML will hold a permanent seat on the Board of Directors of Tech2Health.

Additionally, the Issuer has engaged Winning Media (“WM”) to provide strategic digital media services, marketing, and data analytics services (the “Services”). The Company has agreed to pay WM \$250,000 USD in consideration for the Services to be provided for a 6-month term. WM will not receive any securities of the Company as compensation for the Services. This agreement is arms length.

Finally, the Issuer engaged TDM Financial to provide the Company with marketing solutions such as content creation and distribution, press release distribution, video production, a social media presence and more. In consideration for the services provided by TDM Financial, AIML agrees to pay US\$30,000 USD upon execution of the agreement, with the agreement in effect until October 27th, 2021. The Company is at arm’s length from TDM Financial.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.  
None.
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.  
Please see #1, 2, 3, and 5 for descriptions of acquisitions. There were no dispositions during the period.
8. Describe the acquisition of new customers or loss of customers.  
None.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.  
None.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.  
None.
11. Report on any labour disputes and resolutions of those disputes if applicable.  
None.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.  
None.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.  
The Issuer repaid an arm's length demand loan on behalf of its subsidiary Health Gauge, in the amount of \$159,000.
14. Provide details of any securities issued and options or warrants granted.  
None.

15. Provide details of any loans to or by Related Persons.  
None.
16. Provide details of any changes in directors, officers or committee members.  
Mr Dave Cross joined the company as CFO, replacing Vic Hugo.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.


There is a growing awareness and acceptance amongst the public, healthcare providers, insurers/payors, and regulators towards the use of digital and virtual healthcare in general, with mental healthcare making up an increasing component of that. This trend is expected to continue at double digit growth rates globally for the next several years. Its acceptance has been expedited by the CV-19 pandemic as patients were discouraged from face-to-face medical intervention in all but the most dire of circumstances. The general public has grown to understand the ease and convenience of digital healthcare as a result.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated 05/07/2021.

Tim Daniels  
 Name of Director or Senior  
 Officer  
  
 Signature  
 Executive Chairman  
 Official Capacity

<b>Issuer Details</b>		For Month	Date of Report
Name of Issuer		End	YY/MM/D
AI/ML Innovations Inc.		June 2021	21/07/05
Issuer Address			
Suite 200, 82 Richmond Street East Toronto, Ontario M5C 1P1			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Toronto, ON			(778) 405-0882
Contact Name		Contact Position	Contact Telephone No.
Tim Daniels		Director	250 483-5650
Contact Email Address		Web Site Address	
tim.daniels@aimgl-innovations.com		aimgl-innovations.com	